Dyadic International (NASDAQ: DYAI) announced that its board of directors has appointed Joe Hazelton as president, effective immediately, as part of an ongoing strategic shift to evolve into a revenue-generating provider of ancillary recombinant protein products.
In addition to this new role, Mr. Hazelton will continue as COO, while being responsible for scaling the company’s scientific and commercial initiatives, deepening industry partnerships, oversight of daily operations, ensuring efficient execution of the business strategy, and guiding Dyadic’s corporate rebranding efforts.
“We believe the achievement of these milestones validates our strategy and reflects the growing demand for ancillary recombinant proteins,” said Mark Emalfarb, founder and CEO of Dyadic. “We previously communicated an initial focus in the ancillary protein space, we have successfully executed on key initial agreements, and now we are reaffirming that focus by aligning our leadership team to accelerate growth. Joe’s appointment as President ensures focused and prioritized execution across Dyadic’s technical, operational and commercial efforts.”
In a statement, Mr. Hazelton said, “We see this as a pivotal moment for Dyadic. We’ve proven the commercial readiness of our platforms with valuable partnerships and revenue. Now we’re aligning our organization to scale and expand across the life sciences, food, and nutrition markets. I look forward to working with our leadership team to work to accelerate this momentum, drive operational execution, and deliver tangible value to our shareholders.”
